Sales of Botox Are Less Than Expected, Now What?

Sales of Botox Are Less Than Expected, Now What?

Abbvie, the maker of Botox and the Juvederm collection of fillers, has reported less-than-expected third-quarter 2023 financial results. What does this mean for your practice? You may also be experiencing lower-than-projected revenue, but your expenses have yet to go...
Daxxify Slashes Price to Take Market Share From Botox

Daxxify Slashes Price to Take Market Share From Botox

Daxxify is a new FDA-approved neuromodulator by Revance Therapeutics (“Revance”) designed to soften the look of fine lines and wrinkles. Daxxify differs from Botox and other botulinum toxin injectables, like Xeomin, Juveau, and Dysport, in that it is designed to work...